Cocrystal Pharma (COCP) Competitors $2.25 +0.15 (+7.14%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends COCP vs. KPTI, QNCX, GNLX, PMVP, ENTX, CLSD, IMAB, ELYM, IKNA, and GBIOShould you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Karyopharm Therapeutics (KPTI), Quince Therapeutics (QNCX), Genelux (GNLX), PMV Pharmaceuticals (PMVP), Entera Bio (ENTX), Clearside Biomedical (CLSD), I-Mab (IMAB), Eliem Therapeutics (ELYM), Ikena Oncology (IKNA), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Cocrystal Pharma vs. Karyopharm Therapeutics Quince Therapeutics Genelux PMV Pharmaceuticals Entera Bio Clearside Biomedical I-Mab Eliem Therapeutics Ikena Oncology Generation Bio Karyopharm Therapeutics (NASDAQ:KPTI) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk. Which has more risk and volatility, KPTI or COCP? Karyopharm Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Is KPTI or COCP more profitable? Cocrystal Pharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -58.93%. Karyopharm Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-58.93% N/A -41.25% Cocrystal Pharma N/A -94.62%-78.24% Does the media favor KPTI or COCP? In the previous week, Karyopharm Therapeutics' average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score. Company Overall Sentiment Karyopharm Therapeutics Neutral Cocrystal Pharma Neutral Does the MarketBeat Community believe in KPTI or COCP? Karyopharm Therapeutics received 512 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 76.67% of users gave Cocrystal Pharma an outperform vote while only 72.20% of users gave Karyopharm Therapeutics an outperform vote. CompanyUnderperformOutperformKaryopharm TherapeuticsOutperform Votes53572.20% Underperform Votes20627.80% Cocrystal PharmaOutperform Votes2376.67% Underperform Votes723.33% Do insiders and institutionals have more ownership in KPTI or COCP? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 4.3% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 25.6% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer KPTI or COCP? Karyopharm Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 687.40%. Cocrystal Pharma has a consensus target price of $7.00, suggesting a potential upside of 211.11%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Cocrystal Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, KPTI or COCP? Cocrystal Pharma has lower revenue, but higher earnings than Karyopharm Therapeutics. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$148.44M0.54-$143.10M-$1.14-0.56Cocrystal PharmaN/AN/A-$17.98M-$1.85-1.22 SummaryKaryopharm Therapeutics beats Cocrystal Pharma on 9 of the 14 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Cocrystal Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COCP vs. The Competition Export to ExcelMetricCocrystal PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.89M$6.58B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-1.2210.4689.5817.17Price / SalesN/A195.791,116.12116.95Price / CashN/A57.1642.8237.86Price / Book0.875.094.774.78Net Income-$17.98M$151.83M$120.15M$225.60M7 Day Performance17.92%-2.13%-1.92%-1.23%1 Month Performance4.65%-3.10%11.47%3.36%1 Year Performance19.05%11.54%30.52%16.60% Cocrystal Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COCPCocrystal Pharma2.6621 of 5 stars$2.25+7.1%$7.00+211.1%+21.6%$22.89MN/A-1.2210High Trading VolumeKPTIKaryopharm Therapeutics3.8015 of 5 stars$0.66-5.3%$5.00+654.1%-16.2%$83.67M$148.44M-0.61380QNCXQuince Therapeutics2.8954 of 5 stars$1.88-7.4%$8.50+352.1%+60.4%$82.72MN/A-1.6460Analyst ForecastAnalyst RevisionNews CoverageGNLXGenelux0.8843 of 5 stars$2.39+2.6%$18.25+663.6%-82.9%$82.55M$8,000.00-2.4510PMVPPMV Pharmaceuticals1.7944 of 5 stars$1.59+0.3%$5.80+265.9%-34.5%$82.02MN/A0.0050Positive NewsENTXEntera Bio1.4305 of 5 stars$2.21+2.3%$10.00+352.5%+195.8%$79.07M$130,000.00-8.5020CLSDClearside Biomedical2.8771 of 5 stars$1.03+1.0%$5.33+417.8%-12.8%$78.12M$8.23M-2.2930News CoverageIMABI-Mab2.5162 of 5 stars$0.95-5.1%$8.00+742.6%-38.9%$77.38M$3.27M0.0034Gap DownELYMEliem TherapeuticsN/A$2.60-7.8%N/A-27.5%$77.36MN/A-4.9120IKNAIkena Oncology2.8725 of 5 stars$1.58-4.2%$3.00+89.9%-20.5%$76.25M$659,000.00-1.3470GBIOGeneration Bio2.7569 of 5 stars$1.14-1.7%$7.50+557.9%-30.0%$76.14M$18.58M-0.53150Positive News Related Companies and Tools Related Companies KPTI Competitors QNCX Competitors GNLX Competitors PMVP Competitors ENTX Competitors CLSD Competitors IMAB Competitors ELYM Competitors IKNA Competitors GBIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COCP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.